ClinicalTrials.gg

Program

diroximel fumarate

Also written as “Diroximel fumarate”, “ALKS 8700” and “Diroximel Fumarate”.

Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting, led by Biogen.

Furthest: phase 3, since Dec 16, 20155 company-led studies, 1 open or runningNext primary completion: Jul 28, 2034 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen51 open or runningphase 3since Dec 16, 2015Dec 16, 2015Jul 28, 2034phase 3 · NCT07483632

Also a collaborator on its studies: Alkermes.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2015First study: phase 3 study in Multiple SclerosisFirst studyNCT02634307 · 1,057 enrolled · United States, Belgium, Bulgaria and more
  2. Mar 16, 2017Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT03093324 · 506 enrolled · United States, Germany, Poland
  3. Oct 6, 2021Phase 3 study in Relapsing Forms of Multiple SclerosisNCT05083923 · 136 enrolled · China, Japan
  4. Nov 9, 2021Phase 1 study in Healthy VolunteersNCT05127564 · 32 enrolled · Hong Kong, New Zealand
  5. Feb 26, 2026Phase 3 study in Relapsing Forms of Multiple SclerosisNCT07483632 · 185 planned

Ahead

  1. Jul 28, 2034Primary completion: phase 3 study in Relapsing Forms of Multiple SclerosisNCT07483632

TargetBeta

KEAP1 →read by rule
“Kelch-like ECH-associated protein 1 inhibitor”ChEMBL 37, by rule

Other programs on KEAP1

ProgramCompanyFurthest phaseStudies
Dimethyl FumarateruleBiogenphase 437

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07483632Relapsing Forms of Multiple Sclerosis3Not yet recruitingJul 28, 2034185
NCT05127564Healthy Volunteers · Hong Kong, New Zealand1CompletedJun 9, 202232
NCT05083923Relapsing Forms of Multiple Sclerosis · China, Japan3CompletedSep 11, 2024136
NCT03093324Multiple Sclerosis, Relapsing-Remitting · United States, Germany, Poland3CompletedJun 27, 2019506
NCT02634307Multiple Sclerosis · United States, Belgium, Bulgaria and more3CompletedJun 1, 20211,057

How it is read

Names in the registry

  • “Diroximel fumarate”, 2 entries
  • “ALKS 8700”, 2 entries
  • “Diroximel Fumarate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.